Autolus Therapeutics PLC
NASDAQ:AUTL
Autolus Therapeutics PLC
Revenue
Autolus Therapeutics PLC
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Revenue
$1.7m
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Revenue
$6.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Exscientia PLC
NASDAQ:EXAI
|
Revenue
£20.1m
|
CAGR 3-Years
17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Revenue
$41.6m
|
CAGR 3-Years
55%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Revenue
£249.4m
|
CAGR 3-Years
102%
|
CAGR 5-Years
60%
|
CAGR 10-Years
N/A
|
|
Genus PLC
LSE:GNS
|
Revenue
£673.1m
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
See Also
What is Autolus Therapeutics PLC's Revenue?
Revenue
1.7m
USD
Based on the financial report for Dec 31, 2023, Autolus Therapeutics PLC's Revenue amounts to 1.7m USD.
What is Autolus Therapeutics PLC's Revenue growth rate?
Revenue CAGR 3Y
0%
Over the last year, the Revenue growth was -73%.